CannBioRx Life Sciences is a global pharmaceutical company headquartered in Palo Alto, California which is focused on targeting unmet clinical needs in chronic pain and inflammation by employing combination therapy and innovative research.

CannBioRx is the brainchild of four of the top leading scientists in the biotechnology and pharmaceutical sectors over the last 30 years and is led by a team of world-class scientists who excel in their respective fields.

The company houses three innovative biotech companies under its umbrella.

180 Therapeutics Phase 2B

180 Therapeutics, a clinical-stage company, was founded by Professor Sir Marc Feldmann, Professor Jagdeep Nanchahal, and Dr Glenn Larsen in 2013, and targets as its main indication fibrosis of the hand, later frozen shoulder, liver fibrosis, and post operative delirium.

CannBioRex Pre-Clinical

CannBioRex is a pioneer in the field of synthetic non-psychoactive cannabinoids, and the result of a twenty-year collaboration between Professor Sir Marc Feldmann and Professor Raphael Mechoulam, the pioneer chemist, and so a leading expert in cannabis chemistry.

Katexco Pre-Clinical

Katexco is a second-generation pharmaceutical cannabis company targeting autoimmune diseases by a variety of approaches, including utilizing CBD or related compounds, CB2 agonists, or α7 Nicotinic receptor agonists.

The company will be targeting the following conditions as its primary objectives